Mr Mrs Miss Ms Dr Other

Dr
Laurence
Gainey

Partner & Patent Attorney

Manchester Office

Life sciences

Telephone. +44(0) 161 247 4900
Mobile. +44(0) 778 545 8684
Email. [email protected]

Experience

Laurence is a highly-experienced European and UK qualified patent attorney with over 25 years’ experience handling pharmaceutical and biotechnology subject matter. He has successfully managed patent portfolios on a variety of biotechnology subject matter, including diagnostic tools and targets, personalised healthcare (PHC), antisense oligonucleotide molecules, peptide and antibody (e.g. polyclonal, monoclonal, bispecific and conjugated) therapeutics, as well as handling the IP for small molecule discovery and high profile on sale pharmaceutical products, some with greater than $1bn annual sales.

After gaining a PhD in molecular biology from Reading University, Laurence joined a small biotechnology company to work in the laboratory on virus-based antigen delivery systems. After a couple of years, he moved internally to train as a patent attorney. In the same year as qualifying as European patent attorney Laurence joined the in-house patent department of AstraZeneca Pharmaceutical Ltd. where he worked for over 18 years before joining HGF’s Manchester office as a Patent Director in September 2017.

Qualifications

Patent Attorney

Chartered (UK)
Europe


BSC

Cell and Molecular Biology

PHD

Molecular Biology - Reading University

POSTGRADUATE DIPLOMA OR CERTIFICATE

Certificate in Intellectual Property Law - Queen Mary University of London

Publications

MBL Webinar entitled "Patent Due Diligence - The Fundamental Portfolio Checks Required"

View publication online

Chapter "Patent Considerations When Embarking on New Antisense Drug Programs" for the Open Access book "Antisense RNA Design, Delivery, and Analysis". "

View publication online

Related News

Managing Intellectual Property IP Stars 2023

After months of research, Managing IP has published the IP Stars list for 2023. HGF is delighted to have 23 attorneys from England, Scotland, Ireland, Netherlands and Germany recognised and …

Read article

Profiting from Innovation Within Product Platforms

Innovative businesses should seek to maximise the value they obtain from working collaboratively within a product platform ecosystem. A well-defined IP strategy can help achieve this while increasing total innovation …

Read article
Event - 25th May 2023

New seminar series in Salzburg, Dresden and Hamburg

HGF is organising a new German-speaking seminar series in Salzburg, Dresden, and Hamburg starting May 25 2023. Dates May 25, 2023 at 17:30 – Salzburg June 1 2023 at 17:30 …

Event details

Can Artificial Intelligence save the NHS?

In recent months, it has been almost impossible to escape reports of the staffing crisis in the NHS and the impact this is having on the services the NHS can …

Read article

Spotting innovation in digital health – and can you patent it?

Intellectual Property (IP) can add significant value to your business, providing a competitive edge over the market, as well as demonstrating sound business planning to help secure investment. There are …

Read article

Innovation at the heart of UK medtech strategy

The UK Department of Health and Social Care has recently published the government’s first ever medical technology strategy in an effort to accelerate access to innovative technologies. The strategy document …

Read article

How medtech start-ups can supercharge their IP for fundraising

Why is IP important for fundraising? Intellectual property (IP) rights underpin the value of most medtech start-up companies. IP rights include patents, design rights, trade marks, copyright and trade secrets …

Read article

What is EUDAMED and how will it affect your IP strategy?

The “European database on medical devices”, or “EUDAMED”, is the EU’s IT system created by the new Medical Devices Regulation (MDR) and In Vitro Diagnostics Medical Devices Regulation (IVDR). When …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.